^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    paclitaxel

    i
    Other names: BMY 45622, BMS-181339, NSC-125973, QW-8184, MBT-0206, NK-105, DHP-107
    Company:
    Generic mfg.
    Drug class:
    Tubulin inhibitor
    Related drugs:
    1d
    Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer (clinicaltrials.gov)
    P2, N=45, Recruiting, Ohio State University Comprehensive Cancer Center | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date • Circulating tumor DNA
    |
    cisplatin • carboplatin • paclitaxel
    2d
    A Phase III Study Evaluating YL201 Versus ICC in 2L ESCC (clinicaltrials.gov)
    P3, N=440, Not yet recruiting, MediLink Therapeutics (Suzhou) Co., Ltd.
    New P3 trial
    |
    paclitaxel • docetaxel • irinotecan • YL201
    2d
    A Multicenter Prospective Study Evaluating Concurrent Chemoradiotherapy Following Induction Immunochemotherapy for Esophageal Cancer Based on Dynamic ctDNA Monitoring (clinicaltrials.gov)
    P=N/A, N=30, Recruiting, The Central Hospital of Lishui City | N=51 --> 30
    Enrollment change • IO biomarker • Circulating tumor DNA
    |
    cisplatin • paclitaxel
    2d
    Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients (clinicaltrials.gov)
    P2, N=50, Recruiting, Wake Forest University Health Sciences | Trial completion date: Apr 2026 --> Aug 2026 | Trial primary completion date: Apr 2026 --> Aug 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HER-2 negative • ER negative
    |
    carboplatin • paclitaxel • doxorubicin hydrochloride • cyclophosphamide
    4d
    CHANCES: A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=27, Recruiting, Institut Paoli-Calmettes | Trial completion date: Feb 2026 --> Mar 2027 | Trial primary completion date: Mar 2025 --> Mar 2027
    Trial completion date • Trial primary completion date • First-in-human
    |
    PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA (Breast cancer early onset)
    |
    PD-L1 expression • HER-2 positive • HER-2 amplification • HER-2 expression • BRCA mutation • PD-L1 expression + HER-2 overexpression
    |
    Herceptin (trastuzumab) • paclitaxel • IPH5301
    5d
    Emulation of the KEYNOTE-042 (NCT02220894) Trial Using Specialty Oncology Electronic Health Records Databases (clinicaltrials.gov)
    P=N/A, N=770, Active, not recruiting, Brigham and Women's Hospital
    New trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel
    5d
    LESLIE: LifEStyle Intervention to Enhance Efficacy of Neoadjuvant Therapy in Patients With Triple Negative Breast Cancer (clinicaltrials.gov)
    P2, N=356, Recruiting, Universitaire Ziekenhuizen KU Leuven | Not yet recruiting --> Recruiting | Trial completion date: Mar 2031 --> Sep 2031 | Trial primary completion date: Mar 2028 --> Sep 2028
    Enrollment open • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • cyclophosphamide • epirubicin
    5d
    Long-term outcomes of eribulin‑based neoadjuvant chemotherapy for triple‑negative breast cancer patients stratified by homologous recombination deficiency status: results of the randomized JBCRG-22 study. (PubMed, Breast Cancer Res Treat)
    These findings will help guide the development of eribulin-based neoadjuvant chemotherapy for selected TNBC patients. Our exploratory analysis of LC and NLR results may help inform clinical prediction models for eribulin-treated patients.
    Clinical • Journal • BRCA Biomarker
    |
    HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    HRD • BRCA mutation
    |
    carboplatin • paclitaxel • capecitabine • cyclophosphamide • Halaven (eribulin mesylate)
    6d
    Potential gonadal-beneficial effect of sitagliptin against paclitaxel-induced testicular dysfunction via mediating PERK/CHOP/NLRP3/Sestrin2 signaling pathway. (PubMed, Sci Rep)
    SIT decreases cleaved caspase-3, caspase-3, and Cyt.c levels, verifying its anti-apoptotic features. Overall, SIT ameliorated PTX-provoked testicular dysfunction via mediating PERK/CHOP/NLRP3/Sestrin2 signaling pathway.
    Journal
    |
    CASP3 (Caspase 3) • IL1B (Interleukin 1, beta) • NLRP3 (NLR Family Pyrin Domain Containing 3) • CAT (Catalase)
    |
    paclitaxel
    6d
    Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma (clinicaltrials.gov)
    P2, N=65, Not yet recruiting, Rapa Therapeutics LLC | Trial completion date: Sep 2028 --> Sep 2029 | Trial primary completion date: Mar 2028 --> Mar 2029
    Trial completion date • Trial primary completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF V600
    |
    carboplatin • paclitaxel • temsirolimus • sirolimus • RAPA-201
    6d
    A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01) (clinicaltrials.gov)
    P3, N=450, Not yet recruiting, GlaxoSmithKline | Trial completion date: Jan 2030 --> Jul 2030 | Initiation date: Mar 2026 --> Jun 2026 | Trial primary completion date: Jan 2030 --> Jul 2030
    Trial completion date • Trial initiation date • Trial primary completion date • Platinum resistant
    |
    VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1)
    |
    gemcitabine • paclitaxel • pegylated liposomal doxorubicin • topotecan • mocertatug rezetecan (GSK5733584)
    7d
    DARTBOARD: A Prospective Study of Daily Adaptive Radiotherapy to Better Organ-at-Risk Doses in Head and Neck Cancer (clinicaltrials.gov)
    P2, N=50, Completed, University of Texas Southwestern Medical Center | Trial completion date: Sep 2024 --> Mar 2026
    Trial completion date
    |
    Erbitux (cetuximab) • cisplatin • carboplatin • paclitaxel